Fred Hutch Preclinical Ultrasound

项目摘要/摘要 这项提议是关于Visualsonics Vevo 3100超声波设备，以支持临床前的小动物 弗雷德·哈钦森癌症研究中心(弗雷德·哈奇)、华盛顿大学(UW)和 西雅图儿童医院，NCI指定的弗雷德·哈奇/华盛顿大学癌症联盟的所有成员。新的 超声系统将被安置在非常成功的弗雷德·哈奇临床前成像共享资源中 它是该联盟总体翻译生物成像核心共享资源的一部分。购买一个 Vevo 3100临床前成像系统将提供所需的额外容量和更高质量的图像 啮齿动物模型中肿瘤学研究的可视化。超声已成为高血压病患者的临床前标准。 实体瘤在原位和异位的吞吐量评估和精确度 临床前癌症研究所需的经皮注射技术。 目前，弗雷德·哈奇临床前影像共享资源拥有Visualsonics Vevo 2100超声波 成像单元安装在小动物设施内新装修的超声波套房中。这一现有的仪器 支持至少9个用户项目，涉及三个Fred Hutch部门和三个多学科和/或 多机构研究中心。这些项目的资金来自13个由NIH赞助的赠款和6个非 美国国立卫生研究院赞助的赠款。Vevo 2100也被其他共享资源小组使用，例如临床前 模型核心，以支持NIH资助的额外研究。获取Vevo 3100临床前成像 超声系统将为研究人员提供多种好处，包括提高成像的可用性 通过HD成像和人工制品为先进的癌症研究提供时间和扩展的研究能力 降低，优于Vevo 2100。对超声波机的需求是这样的，现有的 用户发现很难为他们的研究预订足够的时间。首席调查员苏尼尔博士 Hingorani将与临床前成像共享资源总监和相关人员一起支持 通过他广博的超声波专业知识使用这台机器。虽然还有其他Vevo 3100超声波 西雅图地区的系统，我们的用户无法使用这些系统进行各种与后勤和研究相关的工作 理由。通过出色的机构支持，临床前影像共享资源继续 发展并将支持这一新工具，确保高质量的维护和监督。收购 Vevo 3100超声波将满足我们日益增长的需求，并进一步成为推动临床前研究的催化剂 太平洋西北地区的研究。

PROJECT SUMMARY/ ABSTRACT This proposal is for a VisualSonics Vevo 3100 ultrasound unit to support preclinical small animal research at Fred Hutchinson Cancer Research Center (Fred Hutch), University of Washington (UW) and Seattle Children’s Hospital, all members of the NCI-designated Fred Hutch / UW Cancer Consortium. The new ultrasound system will be housed within the highly successful Fred Hutch Preclinical Imaging Shared Resource which is part of the Consortium’s overarching Translational BioImaging Core Shared Resource. Purchase of a Vevo 3100 Preclinical Imaging System will provide needed additional capacity and higher quality image visualization for oncology studies in rodent models. Ultrasound has become the preclinical standard for high- throughput evaluation of solid tumors in both orthotopic and heterotopic locations, and for precision percutaneous injection techniques necessary for preclinical cancer research. Currently, Fred Hutch Preclinical Imaging Shared Resource has a VisualSonics Vevo 2100 ultrasound imaging unit housed in a newly renovated ultrasound suite in the Small Animal Facility. This existing instrument supports at least nine users’ projects across three Fred Hutch Divisions and three multidisciplinary and/or multi-institutional Research Centers. These projects are funded through 13 NIH-sponsored grants and 6 non- NIH sponsored grants. The Vevo 2100 is also used by other shared resource groups, such as the Preclinical Model Core, to support additional NIH-funded research. Acquiring the Vevo 3100 Preclinical Imaging Ultrasound System would provide multiple benefits for researchers, including increased availability for imaging time and expanded research capabilities for advanced cancer studies through HD imaging and artifact reduction, superior to that of the Vevo 2100. The demand for the ultrasound machine is such that existing users find it difficult to book sufficient time for their research studies. The Principal Investigator, Dr. Sunil Hingorani, along with the Preclinical Imaging Shared Resource director and associated personnel, will support the use of this machine through his broad ultrasound expertise. Although there are other Vevo 3100 ultrasound systems in the Seattle area, these are unavailable to our users for a variety of logistical and research-related reasons. Through excellent institutional support, the Preclinical Imaging Shared Resource has continued to grow and will support this new instrument, ensuring high quality maintenance and oversight. The acquisition of the Vevo 3100 ultrasound will meet our growing demand and further serve as a catalyst for driving preclinical research in the Pacific Northwest region.